Strategic Fit Focus on selling to rare disease programs through Homology's gene editing and AAVHSC platform, aligning BD outreach with their niche in genetic medicines and leveraging their IP portfolio to propose collaborative development or access to novel delivery modalities.

Partnership Opportunities Given the Nov 2023 Q32 Bio merger, identify co-development or licensing opportunities that leverage Homology’s preclinical strengths, manufacturing capabilities, and IP to expand pipeline reach or accelerate clinical timelines.

Financial & Funding Levers With funding around 187M and revenue in the 10–25M range, present cost-effective collaboration models, milestone-driven deals, and scalable manufacturing partnerships to de-risk investments and attract future capital inflection.

Risk & Compliance Acknowledge past securities concerns and executive changes; position compliance-led, transparent collaboration proposals with clear governance, data integrity, and milestone transparency to build trust with investors and stakeholders.

Operational Fit Leverage their manufacturing capabilities and 15 AAVHSC IP assets to propose supply agreements, regulatory support packages, and end-to-end development services that complement their internal capabilities while expanding customer access to gene therapies.